Comparison of BCG Tokyo172 Strain Induction Therapy Between Low Dose and Standard Dose for Non-Muscle Invasive Bladder Cancer: Intravesical Instillation of BCG Tokyo172 Strain DOI Creative Commons

Hideyuki Isobe,

Fumitaka Shimizu,

Takeshi Ieda

et al.

Biomedicines, Journal Year: 2025, Volume and Issue: 13(1), P. 174 - 174

Published: Jan. 13, 2025

Objectives: The aim of this study was to identify factors that predict recurrence by comparing low-dose and standard-dose Bacillus Calmette-Guérin (BCG) induction therapy in patients with non-muscle invasive bladder cancer (NMIBC). Methods: A total 273 consecutive NMIBC who received (40 mg) or (80 BCG intravesical instillation between January 2004 December 2023 were analyzed. Recurrence-free survival (RFS) rates assessed using the Kaplan–Meier method log-rank test. Univariate multivariate Cox proportional hazards regression analyses used independent predictors based on Club Urológico Español de Tratamiento Oncológico (CUETO) criteria. Results: test showed older age, low dose, number tumors, a history increased risk significantly. Regarding patients, similar two dose groups. However, younger had significantly lower compared BCG. Multiple analysis confirmed BCG, greater than three significant recurrence. Conclusions: In study, we found associated higher relapse standard doses, especially patients. Age-related differences immune response may influence these patterns.

Language: Английский

Comparison of BCG Tokyo172 Strain Induction Therapy Between Low Dose and Standard Dose for Non-Muscle Invasive Bladder Cancer: Intravesical Instillation of BCG Tokyo172 Strain DOI Creative Commons

Hideyuki Isobe,

Fumitaka Shimizu,

Takeshi Ieda

et al.

Biomedicines, Journal Year: 2025, Volume and Issue: 13(1), P. 174 - 174

Published: Jan. 13, 2025

Objectives: The aim of this study was to identify factors that predict recurrence by comparing low-dose and standard-dose Bacillus Calmette-Guérin (BCG) induction therapy in patients with non-muscle invasive bladder cancer (NMIBC). Methods: A total 273 consecutive NMIBC who received (40 mg) or (80 BCG intravesical instillation between January 2004 December 2023 were analyzed. Recurrence-free survival (RFS) rates assessed using the Kaplan–Meier method log-rank test. Univariate multivariate Cox proportional hazards regression analyses used independent predictors based on Club Urológico Español de Tratamiento Oncológico (CUETO) criteria. Results: test showed older age, low dose, number tumors, a history increased risk significantly. Regarding patients, similar two dose groups. However, younger had significantly lower compared BCG. Multiple analysis confirmed BCG, greater than three significant recurrence. Conclusions: In study, we found associated higher relapse standard doses, especially patients. Age-related differences immune response may influence these patterns.

Language: Английский

Citations

0